Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$86.40 USD

86.40
160,612

+1.49 (1.75%)

Updated May 24, 2024 03:59 PM ET

After-Market: $86.24 -0.16 (-0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ligand Pharmaceuticals (LGND) Stock Moves -0.3%: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $70.86, denoting a -0.3% change from the preceding trading day.

Ligand Pharmaceuticals (LGND) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) closed at $72.19 in the latest trading session, marking a -1.84% move from the prior day.

Ligand (LGND) Up 9% on FDA Nod for Molluscum Infection Gel

by Zacks Equity Research

Following the FDA approval, Ligand's (LGND) Zelsuvmi is the first at-home treatment option available for molluscum contagiosum.

Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research

In the closing of the recent trading day, Ligand Pharmaceuticals (LGND) stood at $70.83, denoting a +0.67% change from the preceding trading day.

Ligand Pharmaceuticals (LGND) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) reachead $70.36 at the closing of the latest trading day, reflecting a +0.46% change compared to its last close.

Ligand Pharmaceuticals (LGND) Just Overtook the 200-Day Moving Average

by Zacks Equity Research

Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?

Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress

by Zacks Equity Research

Ligand (LGND) aims to generate annual core sales of around $290 million by 2028. It expects revenues from royalties to witness a CAGR of 16% over the next five years.

Ligand (LGND) Up 12.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Ligand Pharmaceuticals (LGND) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy

by Zacks Equity Research

Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.

Tharimmune (THAR) Up on Positive Data From Pipeline Candidate

by Zacks Equity Research

Tharimmune (THAR) announces positive data from a phase I study on TH104 and the development timeline in chronic pruritis in primary biliary cholangitis indication.

Arcturus' (ARCT) CF Drug Gets FDA's Orphan Status, Stock Up

by Zacks Equity Research

Arcturus (ARCT) rises 8% as the FDA grants Orphan Drug Designation for its product candidate, ARCT-032, for the treatment of cystic fibrosis.

Acadia (ACAD) Begins Alzheimer's Disease Psychosis Study

by Zacks Equity Research

Acadia (ACAD) initiates a phase II study on ACP-204 in the treatment of Alzheimer's disease psychosis, the first among the three studies planned in the phase II/III clinical program of the candidate.

GSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head Study

by Zacks Equity Research

GSK announces positive data from the DREAMM-7 head-to-head phase III study evaluating Blenrep for second-line treatment of relapsed or refractory multiple myeloma. The study meets its primary endpoint.

Regeneron (REGN), Sanofi's Dupixent Succeeds in 2nd COPD Study

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi (SNY) post positive data from the second COPD study and plan to submit a sBLA to the FDA by the end of 2023.

Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan

by Zacks Equity Research

Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic alternatives to maximize shareholder value. The company cuts its workforce by 72%.

Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How

by Zacks Equity Research

Kiniksa Pharmaceuticals (KNSA) enjoys a good run in the year on the back of solid revenue growth and pipeline updates.

Vertex (VRTX) Gets EU Nod for Kaftrio Use in 2-5 Year Kids

by Zacks Equity Research

The European Commission approves Vertex's (VRTX) Kaftrio for expanded use to treat children aged two to five years with cystic fibrosis.

Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) shares gain 10% year to date on Eylea HD's approval and Dupixent's momentum. Pipeline progress is impressive as well.

Zacks Industry Outlook Highlights Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals

by Zacks Equity Research

Gilead Sciences, CRISPR Therapeutics, ACADIA Pharmaceuticals, Dynavax and Ligand Pharmaceuticals are part of the Zacks Industry Outlook article.

Freeline (FRLN) Shares Rise on Merger Agreement With Syncona

by Zacks Equity Research

Freeline Therapeutics (FRLN) is set to be acquired by Syncona Ltd. The transaction is expected to be closed in the first quarter of 2024. Shares rise.

Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug

by Zacks Equity Research

Mesoblast (MESO) partners with Blood and Marrow Transplant Clinical Trials Network to develop a pivotal study on its lead candidate, Ryoncil, for acute graft versus host disease. The stock rises 11%.

Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down

by Zacks Equity Research

The FDA clears Immix's (IMMX) investigational new drug application for BCMA CAR-T cell therapy, NXC-201, to expand clinical studies in relapsed/refractory AL amyloidosis to the United States. Stock falls.

How Much Upside is Left in Ligand (LGND)? Wall Street Analysts Think 90.66%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 90.7% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Avita (RCEL) Falls 19% on Lowered 2023 Revenue Guidance

by Zacks Equity Research

Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.